← Back to patent-cliff list
CP-383
Tier C — Watch / tradeCP-383
Tasca Therapeutics Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Bladder cancer, Non-small cell lung cancer, Colorectal cancer, Solid tumour, Head and neck squamous cell carcinoma, Small cell lung cancer, Pancreatic cancer
Regional status
US
Phase II
2025-08-27
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CP-383?
Approved indications include: Bladder cancer, Non-small cell lung cancer, Colorectal cancer, Solid tumour, Head and neck squamous cell carcinoma, Small cell lung cancer, Pancreatic cancer.
When does the CP-383 patent expire?
No public expiry year is available for CP-383 yet; this page updates once verified.
How do I get a quote for CP-383 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30